Pierre-Olivier Gaudreau, MD, PhD, MPs, FRCPC

CCTG Senior Investigator, Investigational New Drug Program

Dr. Gaudreau is a medical oncologist and hematologist whose research focuses on early-phase clinical trials, mechanisms of response and resistance to immunotherapy and innovative anti-cancer agents, and thoracic malignancies. He completed his training at the University of Montreal (MD, PhD), the University of Texas MD Anderson Cancer Center (doctoral research fellowship) and McGill University (post-doctoral research fellowship). Dr. Gaudreau joined the Canadian Clinical Trials Group (CCTG) in 2020 as a Senior Investigator for the Investigational New Drug Program and the Thoracic Oncology Disease Site Committee. He is also an Assistant Professor in the Department of Oncology at Queen’s University, and practices as a thoracic medical oncologist at the Kingston Health Sciences Centre.

Areas of expertise: early-phase clinical trials, translational research, immuno-oncology, lung cancer

Research interests: early-phase clinical trials, investigational new drugs, tumor drug resistance, mechanisms of resistance to immunotherapy, novel immunotherapy combination strategies, lung cancer

Select Publications:

Gaudreau, P.-O., Negrao, M.V., Mitchell, K.G., Reuben, A., Corsini, E.M., Li, J., Karpinets, T., Wang, Q., Diao, L., Wang, J., Federico, L., Parra-Cuentas, E.R., Khairullah, R., Behrens, C., Correa, A.M., Gomez, D., Little, L., Gumbs, C., Kadara, H., Fujimoto, J., McGrail, D.J., Vaporciyan, A.A., Swisher, S., Walsh, G., Antonoff, M.B., Weissferdt, A., Tran, H., Roarty, E., Haymaker, C., Bernatchez, C., Zhang, J., Futreal, P.A. Wistuba, I.I., Tina Cascone, T., Heymach, J.V., Sepesi, B., Zhang, J. & Don L. Gibbons, D.L. Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B cell Infiltration in Resectable Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2021 Jan;16(1):127-139. doi: 10.1016/j.jtho.2020.09.027.

Gaudreau, P.-O., Jack Lee, J., Heymach, J., & Gibbons, D. L. Phase I/II Trial of Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in advanced NSCLC: Early Trial Report. Clinical Lung Cancer. 2020 Jul;21(4):384-388. doi: 10.1016/j.cllc.2020.02.019. Epub 2020 Mar 4.

Helmink, B.A., Reddy, S.M., Gao, J., Zhang, S., Yizhak, K., Sade-Feldman, M., Blando, J., Han, H., Zhao, H., Tawbi, H.A., Amaria, R.N., Davies, M.A., Hwu, P., Lee, J.E., Gershenwald, J., Burton, E.M., Haydu, L., Lazar, A.J., Hudgens, C.W., Cogdill, A., Krijgskman, O., Rozeman, L., Blank, C., Schumacher, T., Keung, E., Gaudreau, P.-O., Gopalakrishnan, V., Reuben, A., Spencer, C.N., Butterfield, L., Allison, J., Tetzlaff, M.T., Wu, C., Petitprez, F., Fridman, W.H., Sautes-Fridman, C., Hacohen, N., Sharma, P., Wang, L. & Wargo, J.A. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 Jan 15. doi: 10.1038/s41586-019-1922-8.

Jacquelot, N., Yamazaki, T., Roberti, M.P., Andrews, M.C., Verlingue, L., Ferrere, G., Duong, C.P.M., Becharef, S., Vétizou, M., Daillère, R., Messaoudene, M., Enot, D.P., Stol, G., Ugel, S., Marigo, I., Ngiow, S.F., Marabelle, A., Prevost-Blondel, A., Gaudreau, P.-O., Gopalakrishnan, V., Eggermont, A.M., Opolon, P., Poirier-Colame, V., Klein, C., Madonna, G., Ascierto, P.A., Sucker, A., Schadendorf, D., Smyth, M.J., Soria, J.C., Kroemer, G., Bronte, V., Wargo, J.A. & Zitvogel, L. Sustained Type I IFN signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019 Sep 3. doi: 10.1038/s41422-019-0224-x.

Gaudreau, P.-O., Clairefond, S., Class, C., Boulay, P.-L., Chrobak, P., Allard, B., Pommey, S., Do, K.-A., Saad, Fr., Young, M. & Stagg, J. WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. Oncoimmunology, 2019 Mar 22;8(5):e1581545. doi:10.1080/2162402X.2019.1581545.

For a full list of publications please visit Pub Med.